PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
DOCG.L vs. BTEE.L
Performance
Return for Risk
Dividends
Drawdowns
Volatility

DOCG.L vs. BTEE.L

Last updated Apr 1, 2026

Compare and contrast key facts about L&G Healthcare Breakthrough UCITS ETF (DOCG.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L).

DOCG.L and BTEE.L are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. DOCG.L is a passively managed fund by Legal & General that tracks the performance of the MSCI World/Health Care NR USD. It was launched on Jun 26, 2019. BTEE.L is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology TR USD. It was launched on Mar 5, 2018. Both DOCG.L and BTEE.L are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

DOCG.L vs. BTEE.L - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in L&G Healthcare Breakthrough UCITS ETF (DOCG.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

DOCG.L vs. BTEE.L - Yearly Performance Comparison

2026 (YTD)2025202420232022202120202019
DOCG.L
L&G Healthcare Breakthrough UCITS ETF		-8.11%16.50%3.57%-6.64%-25.94%1.46%63.33%0.69%
BTEE.L
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)		2.93%23.36%0.03%0.55%-1.41%0.37%23.80%7.54%
Different Trading Currencies

DOCG.L is traded in GBp, while BTEE.L is traded in USD. To make them comparable, the BTEE.L values have been converted to GBp using the latest available exchange rates.

Returns By Period

In the year-to-date period, DOCG.L achieves a -8.11% return, which is significantly lower than BTEE.L's 2.93% return.

DOCG.L

1D
0.82%
1M
-8.16%
YTD
-8.11%
6M
8.74%
1Y
17.96%
3Y*
0.93%
5Y*
-4.99%
10Y*
—

BTEE.L

1D
2.43%
1M
-2.57%
YTD
2.93%
6M
21.25%
1Y
33.73%
3Y*
9.75%
5Y*
5.09%
10Y*
—
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

L&G Healthcare Breakthrough UCITS ETF

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)

Often compared with DOCG.L:
DOCG.L vs. DRDR.LDOCG.L vs. VBRDOCG.L vs. SWDA.LDOCG.L vs. BIOG.LDOCG.L vs. HLTW.LDOCG.L vs. ROBG.LDOCG.L vs. WHCE.L
Often compared with BTEE.L:
BTEE.L vs. VOOBTEE.L vs. NBTK.DEBTEE.L vs. WBIO.LBTEE.L vs. DOCT.LBTEE.L vs. BIGT.LBTEE.L vs. GNOG.LBTEE.L vs. WHCE.L

DOCG.L vs. BTEE.L - Expense Ratio Comparison

DOCG.L has a 0.49% expense ratio, which is higher than BTEE.L's 0.35% expense ratio.

DOCG.L
L&G Healthcare Breakthrough UCITS ETF
BTEE.L
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)

Return for Risk

DOCG.L vs. BTEE.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
DOCG.L
DOCG.L Risk / Return Rank: 4242
Overall Rank
DOCG.L Sharpe Ratio Rank: 4646
Sharpe Ratio Rank
DOCG.L Sortino Ratio Rank: 4747
Sortino Ratio Rank
DOCG.L Omega Ratio Rank: 3939
Omega Ratio Rank
DOCG.L Calmar Ratio Rank: 4242
Calmar Ratio Rank
DOCG.L Martin Ratio Rank: 3636
Martin Ratio Rank
BTEE.L
BTEE.L Risk / Return Rank: 8484
Overall Rank
BTEE.L Sharpe Ratio Rank: 8383
Sharpe Ratio Rank
BTEE.L Sortino Ratio Rank: 8484
Sortino Ratio Rank
BTEE.L Omega Ratio Rank: 7676
Omega Ratio Rank
BTEE.L Calmar Ratio Rank: 8585
Calmar Ratio Rank
BTEE.L Martin Ratio Rank: 9191
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DOCG.L vs. BTEE.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for L&G Healthcare Breakthrough UCITS ETF (DOCG.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

DOCG.LBTEE.LDifference

Sharpe ratio

Return per unit of total volatility

0.84

1.54

-0.70

Sortino ratio

Return per unit of downside risk

1.29

2.09

-0.80

Omega ratio

Gain probability vs. loss probability

1.16

1.27

-0.12

Calmar ratio

Return relative to maximum drawdown

1.09

2.59

-1.50

Martin ratio

Return relative to average drawdown

3.29

9.92

-6.63

Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DOCG.L vs. BTEE.L - Sharpe Ratio Comparison

The current DOCG.L Sharpe Ratio is 0.84, which is lower than the BTEE.L Sharpe Ratio of 1.54. The chart below compares the historical Sharpe Ratios of DOCG.L and BTEE.L, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Loading graphics...

Sharpe Ratios by Period

DOCG.LBTEE.LDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.84

1.54

-0.70

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.23

0.25

-0.47

Sharpe Ratio (All Time)

Calculated using the full available price history

0.17

0.32

-0.15

Correlation

The correlation between DOCG.L and BTEE.L is 0.72, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.

Dividends

DOCG.L vs. BTEE.L - Dividend Comparison

DOCG.L has not paid dividends to shareholders, while BTEE.L's dividend yield for the trailing twelve months is around 0.37%.

TTM20252024202320222021202020192018
DOCG.L
L&G Healthcare Breakthrough UCITS ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
BTEE.L
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)		0.37%0.37%0.46%0.39%0.44%0.25%0.17%0.14%0.07%

Drawdowns

DOCG.L vs. BTEE.L - Drawdown Comparison

The maximum DOCG.L drawdown since its inception was -51.45%, which is greater than BTEE.L's maximum drawdown of -30.88%. Use the drawdown chart below to compare losses from any high point for DOCG.L and BTEE.L.

Loading graphics...

Drawdown Indicators

DOCG.LBTEE.LDifference

Max Drawdown

Largest peak-to-trough decline

-51.45%

-38.29%

-13.16%

Max Drawdown (1Y)

Largest decline over 1 year

-15.66%

-14.72%

-0.94%

Max Drawdown (5Y)

Largest decline over 5 years

-49.65%

-38.29%

-11.36%

Current Drawdown

Current decline from peak

-33.67%

-4.85%

-28.82%

Average Drawdown

Average peak-to-trough decline

-26.99%

-13.78%

-13.21%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.17%

2.97%

+2.20%

Volatility

DOCG.L vs. BTEE.L - Volatility Comparison

The current volatility for L&G Healthcare Breakthrough UCITS ETF (DOCG.L) is 6.30%, while iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) has a volatility of 7.25%. This indicates that DOCG.L experiences smaller price fluctuations and is considered to be less risky than BTEE.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading graphics...

Volatility by Period

DOCG.LBTEE.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.30%

7.25%

-0.95%

Volatility (6M)

Calculated over the trailing 6-month period

14.05%

14.10%

-0.05%

Volatility (1Y)

Calculated over the trailing 1-year period

21.34%

22.04%

-0.70%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

21.92%

20.78%

+1.14%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.40%

22.43%

+0.97%